News from mitsubishi tanabe pharma america, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Mar 18, 2021, 09:12 ET Post-Hoc Analysis of Phase 3 Study Examines Effect of Early Intervention with Edaravone on Survival and Disease Progression Milestone Events in ALS Patients

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced a post-hoc analysis of its Phase 3 edaravone study reviewing the results of intravenous ...

Mar 17, 2021, 10:30 ET Mitsubishi Tanabe Pharma America Presents Data on Impact of ALS Symptoms on Patients' Ability to Independently Conduct Daily Activities

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced findings from a new analysis evaluating the impact of symptom progression on the...

Mar 03, 2021, 13:00 ET Mitsubishi Tanabe Pharma America Announces Establishment of NeuroDiscovery Lab Research Base in Cambridge, Mass.

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that Mitsubishi Tanabe Pharma Holdings America, Inc. (MTHA) plans to establish a new...

Feb 08, 2021, 09:12 ET Mitsubishi Tanabe Pharma America Celebrates Five Years of Dedication to the ALS Community in the U.S.

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today celebrated its five-year anniversary of being established in the United States in 2016. MTPA has...

Jan 21, 2021, 08:30 ET Mitsubishi Tanabe Pharma America and Aquestive Therapeutics Announce U.S. Licensing and Supply Deal for Riluzole Oral Film for ALS Treatment

Mitsubishi Tanabe Pharma America, Inc. (MTPA) and Aquestive Therapeutics, Inc. (NASDAQ: AQST) today announced a licensing and supply deal for the U.S....

Jan 14, 2021, 09:00 ET Mitsubishi Tanabe Pharma America Announces Enhancements to Out-Of-Pocket Assistance Program for Eligible ALS Patients Treated with RADICAVA® (edaravone)

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced upgrades to its out-of-pocket assistance program that aim to provide enhanced support...

Jan 07, 2021, 09:00 ET Mitsubishi Tanabe Pharma America Revises REFINE-ALS Biomarker Study Process to Enable Remote Participation

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced revisions to the REFINE-ALS biomarker study protocol to address the safety of people...

Dec 22, 2020, 09:00 ET Mitsubishi Tanabe Pharma America Announces Initiation of Open-Label Extension Study of Oral Edaravone in ALS

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the initiation of a long-term safety extension study (MT-1186-A03) to the ongoing Phase ...

Dec 14, 2020, 09:00 ET Mitsubishi Tanabe Pharma America Announces Initiation of Postmarketing Commitment Study Assessing Daily Dosing of Oral Edaravone in Patients with ALS

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the initiation of a global clinical study exploring daily dosing of an investigational...

Dec 11, 2020, 07:00 ET Mitsubishi Tanabe Pharma America Presents Real-World Experience Outcomes During IV Edaravone Treatment at Virtual 31st International Symposium on ALS/MND

Mitsubishi Tanabe Pharma America, Inc. (MTPA) and Soleo Health today announced a virtual poster presentation reviewing the analysis of real-world...

Dec 03, 2020, 09:00 ET Mitsubishi Tanabe Pharma America Announces Presentations of ALS Data at Virtual 31st International Symposium on ALS/MND

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced three amyotrophic lateral sclerosis (ALS) presentations as part of the Motor Neurone...

Nov 30, 2020, 09:00 ET Post-Hoc Analysis of ALS Treatment Study Looks at Multiple Staging Systems

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced results from a post-hoc analysis that examined the use of clinical staging systems to...

Nov 09, 2020, 11:00 ET Mitsubishi Tanabe Pharma America Announces the Global Phase 3 Study of Oral Edaravone for ALS has Completed Enrollment

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that patient enrollment has been completed for the global Phase 3 open-label study...

Oct 27, 2020, 10:00 ET Mitsubishi Tanabe Pharma America Celebrates ALS Caregiver & Screenwriter Featured In MDA Kevin Hart Kids Telethon

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that Aleia Kristene Asbey, aspiring screenwriter and participant in the ALSO US™...

Oct 09, 2020, 09:00 ET Mitsubishi Tanabe Pharma America Announces Poster Presentation of ALS Data at American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) 2020 Meeting

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced a poster presentation of a Phase 3 edaravone study post-hoc analysis assessing...

Sep 30, 2020, 09:00 ET Mitsubishi Tanabe Pharma America Announces Presentations At Northeast Amyotrophic Lateral Sclerosis 19th Annual Meeting

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced four presentations on amyotrophic lateral sclerosis (ALS) will be shared as part of the ...

Aug 24, 2020, 09:00 ET Mitsubishi Tanabe Pharma America Announces Enrollment Has Resumed For The Global Phase 3 Study Of Oral Edaravone For ALS

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that the global Phase 3 study to evaluate the long-term safety and tolerability of an...

Aug 06, 2020, 09:00 ET Mitsubishi Tanabe Pharma America Honors Third Anniversary Of RADICAVA® (edaravone) In The U.S. & Company's Support Of ALS Community

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced updates related to the company's commitment to the amyotrophic lateral sclerosis (ALS)...

Jun 19, 2020, 13:41 ET Phase-3 Clinical Trial of MT-7117 INITIATED IN THE U.S. for Rare DiseaseS, Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP)

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that Mitsubishi Tanabe Pharma Development America, Inc. (MTDA) has initiated a Phase-3...

May 20, 2020, 09:00 ET Mitsubishi Tanabe Pharma America Announces Launch Of The JourneyMate Program, Offering Live Nurse Educational Phone Support For ALS Patients And Caregivers

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the launch of RADICAVA® (edaravone) JourneyMate™, a new program connecting people with...

May 05, 2020, 09:14 ET Mitsubishi Tanabe Pharma America Marks Third Anniversary Of FDA Approval And Reports More Than 5,000 Patients With ALS Treated With RADICAVA® (edaravone)

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today reported that more than 5,000 people with amyotrophic lateral sclerosis (ALS) have received the...

Mar 24, 2020, 13:02 ET New Post-hoc Analysis of Phase 3 Study Examines Edaravone in ALS Patients with Bulbar and Limb Onset

Mitsubishi Tanabe Pharma America, Inc. (MTPA) announced the presentation today of a new post-hoc analysis assessing its Phase 3 edaravone study...

Dec 04, 2019, 16:34 ET Mitsubishi Tanabe Pharma America to Present Real-World Data on RADICAVA® (edaravone) for ALS at the 30th International Symposium on ALS/MND

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of a new analysis examining real-world clinical outcomes of treatment...

Dec 02, 2019, 10:00 ET Mitsubishi Tanabe Pharma America To Spotlight Progress In ALS Research At 30th International Symposium On ALS/MND

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced six presentations on amyotrophic lateral sclerosis (ALS), including new results...

Nov 25, 2019, 10:00 ET Mitsubishi Tanabe Pharma America Announces Initiation of Phase 3 Study Evaluating Investigational Oral Formulation of Edaravone for ALS

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the initiation of a global Phase 3 study evaluating the long-term safety and...